Baird raised the firm’s price target on Bright Minds (DRUG) to $82 from $75 and keeps an Outperform rating on the shares. The firm updated its model as the BMB-105 Pader-Willi program holds promise.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG: